JK-1201I

DRUG5 trials

Sponsors

JenKem Technology Co., Ltd.

Conditions

Brain MetastasasesGlioblastoma Multiforme (GBM)Small Cell Lung CancerSmall Cell Lung Cancer (SCLC)Solid TumorTriple Negative Breast Cancer (TNBC)

Phase 1

Safety, Tolerability and Pharmacokinetics of Injectable PEG-Irinotecan (JK-1201I) in Patients with Malignant Solid Tumor

CompletedNCT04366648

JenKem Technology Co., Ltd.Solid Tumor

Start: 2018-05-04End: 2021-03-31Updated: 2024-09-04

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

JenKem Technology Co., Ltd.Small Cell Lung Cancer (SCLC)

Start: 2021-11-11End: 2023-03-31Target: 63Updated: 2022-01-05

Phase 2

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

RecruitingNCT06595186

JenKem Technology Co., Ltd.Glioblastoma Multiforme (GBM)

Start: 2022-10-31End: 2026-12-16Target: 25Updated: 2024-09-19

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

Not yet recruitingNCT06586866

JenKem Technology Co., Ltd.Brain Metastasases, Triple Negative Breast Cancer (TNBC)

Start: 2024-09-26End: 2026-10-26Target: 25Updated: 2024-09-19

Phase 3

JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

Not yet recruitingNCT06581380

JenKem Technology Co., Ltd.Small Cell Lung Cancer

Start: 2024-09-16End: 2028-04-16Target: 394Updated: 2024-09-03